Aaron Stiefel has handled a vast array of major federal and state court litigations as well as arbitrations. Mr. Stiefel now concentrates his practice in the area of intellectual property litigation, drawing on his graduate degree in chemistry and his wealth of general litigation experience.
全部显示Mr. Stiefel has represented leading research-based pharmaceutical and biotechnology companies, such as Pfizer Inc, and Novartis, in all aspects of complex patent litigations. His experience includes bringing and defending patent infringement actions concerning antibiotics, antihypertensives, antifungal medications, treatments for erectile dysfunction, the cloning of alpha-interferon, testing of blood for hepatitis C infection, monoclonal antibodies, contact lenses, surgical devices, methods for producing transgenic mice and data storage products. Mr. Stiefel litigates against other research-based companies and has also litigated claims brought against generic drug manufacturers under the Hatch-Waxman Act. Mr. Stiefel has counseled clients with respect to a host of patent law issues and has authored articles and lectured on patent law. Mr. Stiefel has also represented pharmaceutical companies regarding false advertising and unfair competition claims.
Most recently, Mr. Stiefel acted as lead counsel in preserving Pfizer’s patent exclusivity for its blockbuster drug Viagra®, defeating a challenge by Teva Pharmaceuticals USA Inc., which sought FDA approval to sell a generic version of the drug. After a 12-day bench trial, the U.S. District Court for the Eastern District of Virginia ruled that a Pfizer patent claiming the use of Viagra® to treat erectile dysfunction would be infringed by Teva’s proposed copy. The court rejected Teva’s arguments that the Pfizer patent is invalid and unenforceable. Pfizer Inc, et al. v. Teva Pharmaceuticals USA Inc., 2011 U.S. Dist. Lexis 90021 (E. D. Va. August 12, 2011).
Mr. Stiefel has represented both plaintiffs and defendants at both the trial court and appellate levels in commercial litigation matters involving, inter alia, breach of contract and breach of fiduciary duty claims, product liability claims, alleged violations of the securities laws, bankruptcy claims and claims regarding real property taxes.
Mr. Stiefel has handled jury trials, bench trials, Markman hearings and arbitrations, and has argued before both federal and state appellate courts and trial courts. Mr. Stiefel also spent time as trial counsel in the office of the New York City Corporation Counsel. He is a member of the American Bar Association, the New York State Bar Association, the Federal Circuit Bar Association and the New Jersey Intellectual Property Law Association.